We conducted two replicate @-week , randomized , double-blind , phase @ trials ( INPULSIS-@ and INPULSIS-@ ) to evaluate the efficacy and safety of @ mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis .